Last reviewed · How we verify
Test Drug (JDP-205)
Test Drug (JDP-205) is a small molecule that targets a specific molecular pathway.
Test Drug (JDP-205) is a small molecule that targets a specific molecular pathway. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | Test Drug (JDP-205) |
|---|---|
| Also known as | QUZYTTIR |
| Sponsor | JDP Therapeutics, Inc. |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
While the exact mechanism of action is not publicly disclosed, it is believed to modulate a key signaling pathway involved in the disease process.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Headache
- Nausea
- Dizziness
Key clinical trials
- Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria (PHASE3)
- Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Test Drug (JDP-205) CI brief — competitive landscape report
- Test Drug (JDP-205) updates RSS · CI watch RSS
- JDP Therapeutics, Inc. portfolio CI